Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$39.21
-0.82-2.05%
al cierre: -
$39.21
0.000.00%
After hour: 4:35 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Exelixis Inc ha un obiettivo di prezzo di consenso pari a $42.04, stabilito in base alle ultime valutazioni degli analisti di 25. Le ultime 3 valutazioni degli analisti sono state rilasciate da Morgan Stanley, Goldman Sachs y Barclays il septiembre 17, 2025. Con un obiettivo di prezzo medio di $45.67 tra le Morgan Stanley, Goldman Sachs y Barclays, c'è un implicito 16.47% upside per Exelixis Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Morgan Stanley
Goldman Sachs
Barclays
HC Wainwright & Co.
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Exelixis
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/17/2025 | 27.52% | Morgan Stanley | $46 → $50 | Maintains | Overweight | |||
09/17/2025 | 19.87% | Goldman Sachs | → $47 | Initiates | → Buy | |||
09/17/2025 | 2.01% | Barclays | → $40 | Initiates | → Equal-Weight | |||
08/12/2025 | 17.32% | HC Wainwright & Co. | $53 → $46 | Maintains | Buy | |||
07/30/2025 | -3.09% | UBS | $43 → $38 | Maintains | Neutral | |||
07/29/2025 | 24.97% | Truist Securities | $56 → $49 | Maintains | Buy | |||
07/29/2025 | 17.32% | Morgan Stanley | $48 → $46 | Maintains | Overweight | |||
07/29/2025 | 14.77% | RBC Capital | $50 → $45 | Maintains | Sector Perform | |||
07/29/2025 | 27.52% | JMP Securities | $50 → $50 | Reiterates | Market Outperform → Market Outperform | |||
07/29/2025 | 14.77% | Guggenheim | $45 → $45 | Reiterates | Buy → Buy | |||
07/29/2025 | 4.57% | Stifel | $38 → $41 | Maintains | Hold | |||
07/22/2025 | 22.42% | Morgan Stanley | $47 → $48 | Maintains | Overweight | |||
07/15/2025 | 42.82% | Truist Securities | $55 → $56 | Maintains | Buy | |||
07/11/2025 | 9.67% | UBS | $38 → $43 | Maintains | Neutral | |||
07/10/2025 | 2.01% | Barclays | $29 → $40 | Maintains | Equal-Weight | |||
06/30/2025 | 35.17% | HC Wainwright & Co. | $47 → $53 | Maintains | Buy | |||
06/24/2025 | 53.02% | Stephens & Co. | $29 → $60 | Upgrade | Equal-Weight → Overweight | |||
06/23/2025 | 40.27% | Truist Securities | $43 → $55 | Reiterates | Buy → Buy | |||
06/23/2025 | 27.52% | JMP Securities | $47 → $50 | Maintains | Market Outperform | |||
06/12/2025 | 19.87% | HC Wainwright & Co. | $40 → $47 | Maintains | Buy | |||
06/05/2025 | 17.32% | B of A Securities | $45 → $46 | Maintains | Neutral | |||
05/15/2025 | 42.82% | Citigroup | $45 → $56 | Maintains | Buy | |||
05/14/2025 | -3.09% | Stifel | $36 → $38 | Maintains | Hold | |||
05/14/2025 | 2.01% | RBC Capital | $40 → $40 | Reiterates | Outperform → Outperform | |||
05/14/2025 | 19.87% | Morgan Stanley | $40 → $47 | Maintains | Overweight | |||
04/17/2025 | 4.57% | JMP Securities | $41 → $41 | Reiterates | Market Outperform → Market Outperform | |||
03/27/2025 | 2.01% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
03/13/2025 | 2.01% | RBC Capital | $38 → $40 | Maintains | Outperform | |||
02/24/2025 | -8.19% | Wells Fargo | $36 → $36 | Downgrade | Overweight → Equal-Weight | |||
02/13/2025 | -26.04% | Barclays | $25 → $29 | Maintains | Equal-Weight | |||
02/13/2025 | 2.01% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
02/12/2025 | 14.77% | Citigroup | $38 → $45 | Maintains | Buy | |||
02/12/2025 | 7.12% | Guggenheim | $42 → $42 | Reiterates | Buy → Buy | |||
02/12/2025 | -26.04% | Stephens & Co. | $29 → $29 | Reiterates | Equal-Weight → Equal-Weight | |||
02/12/2025 | -8.19% | Stifel | $30 → $36 | Maintains | Hold | |||
02/12/2025 | -3.09% | Piper Sandler | $37 → $38 | Maintains | Overweight | |||
01/28/2025 | -13.29% | UBS | $30 → $34 | Maintains | Neutral | |||
01/27/2025 | 4.57% | JMP Securities | $41 → $41 | Maintains | Market Outperform | |||
01/27/2025 | 9.67% | Truist Securities | $42 → $43 | Maintains | Buy | |||
01/27/2025 | -26.04% | Stephens & Co. | $29 → $29 | Reiterates | Equal-Weight → Equal-Weight | |||
01/27/2025 | 2.01% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
01/27/2025 | 2.01% | Morgan Stanley | $30 → $40 | Upgrade | Equal-Weight → Overweight | |||
01/24/2025 | -15.84% | Oppenheimer | $41 → $33 | Downgrade | Outperform → Perform | |||
01/23/2025 | 4.57% | JMP Securities | $41 → $41 | Reiterates | Market Outperform → Market Outperform | |||
01/22/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
01/16/2025 | 4.57% | Oppenheimer | $38 → $41 | Maintains | Outperform | |||
01/15/2025 | 7.12% | Truist Securities | $38 → $42 | Maintains | Buy | |||
01/15/2025 | 4.57% | JMP Securities | $34 → $41 | Maintains | Market Outperform | |||
01/13/2025 | -5.64% | Piper Sandler | $36 → $37 | Maintains | Overweight | |||
01/10/2025 | 2.01% | HC Wainwright & Co. | $29 → $40 | Maintains | Buy | |||
01/07/2025 | 7.12% | Guggenheim | $33 → $42 | Maintains | Buy | |||
12/23/2024 | — | Brookline Capital | — | Initiates | → Buy | |||
12/20/2024 | 2.01% | BMO Capital | $36 → $40 | Downgrade | Outperform → Market Perform | |||
12/17/2024 | -0.54% | B of A Securities | $35 → $39 | Downgrade | Buy → Neutral | |||
10/30/2024 | -15.84% | Guggenheim | $32 → $33 | Maintains | Buy | |||
10/30/2024 | -26.04% | Stephens & Co. | $23 → $29 | Maintains | Equal-Weight | |||
10/30/2024 | -8.19% | Piper Sandler | $33 → $36 | Maintains | Overweight | |||
10/30/2024 | -13.29% | RBC Capital | $34 → $34 | Reiterates | Outperform → Outperform | |||
10/30/2024 | -3.09% | Truist Securities | $33 → $38 | Maintains | Buy | |||
10/30/2024 | -8.19% | Wells Fargo | $32 → $36 | Maintains | Overweight | |||
10/30/2024 | -8.19% | BMO Capital | $29 → $36 | Maintains | Outperform | |||
10/21/2024 | -13.29% | TD Cowen | $27 → $34 | Maintains | Buy | |||
10/16/2024 | -23.49% | Stifel | $26 → $30 | Maintains | Hold | |||
10/16/2024 | -13.29% | RBC Capital | $30 → $34 | Maintains | Outperform | |||
10/16/2024 | -13.29% | JMP Securities | $29 → $34 | Maintains | Market Outperform | |||
10/15/2024 | -23.49% | Morgan Stanley | $28 → $30 | Maintains | Equal-Weight | |||
10/15/2024 | -18.39% | B of A Securities | $30 → $32 | Maintains | Buy | |||
10/11/2024 | -26.04% | JMP Securities | $29 → $29 | Reiterates | Market Outperform → Market Outperform | |||
10/11/2024 | -28.59% | Morgan Stanley | $26 → $28 | Maintains | Equal-Weight | |||
10/04/2024 | -23.49% | RBC Capital | $27 → $30 | Maintains | Outperform | |||
09/26/2024 | -31.14% | RBC Capital | $27 → $27 | Reiterates | Outperform → Outperform | |||
09/20/2024 | -26.04% | JMP Securities | $29 → $29 | Reiterates | Market Outperform → Market Outperform | |||
09/19/2024 | -23.49% | UBS | → $30 | Initiates | → Neutral | |||
09/18/2024 | -26.04% | HC Wainwright & Co. | $29 → $29 | Reiterates | Buy → Buy | |||
08/08/2024 | -15.84% | Truist Securities | $32 → $33 | Reiterates | Buy → Buy | |||
08/07/2024 | -26.04% | JMP Securities | $27 → $29 | Maintains | Market Outperform | |||
08/07/2024 | -31.14% | RBC Capital | $27 → $27 | Reiterates | Outperform → Outperform | |||
07/30/2024 | -26.04% | Oppenheimer | $29 → $29 | Maintains | Outperform | |||
05/14/2024 | -41.34% | Stephens & Co. | → $23 | Initiates | → Equal-Weight | |||
05/03/2024 | -28.59% | HC Wainwright & Co. | $28 → $28 | Reiterates | Buy → Buy | |||
05/01/2024 | -31.14% | TD Cowen | $25 → $27 | Maintains | Buy | |||
04/11/2024 | -36.24% | Barclays | $25 → $25 | Downgrade | Overweight → Equal-Weight | |||
04/10/2024 | -31.14% | JMP Securities | $27 → $27 | Reiterates | Market Outperform → Market Outperform | |||
02/07/2024 | -28.59% | RBC Capital | $26 → $28 | Maintains | Outperform | |||
02/02/2024 | -36.24% | Stifel | $23 → $25 | Maintains | Hold | |||
01/30/2024 | -36.24% | Barclays | $24 → $25 | Maintains | Overweight | |||
12/19/2023 | -31.14% | BTIG | → $27 | Initiates | → Buy | |||
12/15/2023 | -20.94% | Citigroup | → $31 | Initiates | → Buy | |||
12/14/2023 | -31.14% | JMP Securities | $27 → $27 | Reiterates | Market Outperform → Market Outperform | |||
12/13/2023 | -33.69% | RBC Capital | $26 → $26 | Reiterates | Outperform → Outperform | |||
11/13/2023 | -31.14% | JMP Securities | → $27 | Reiterates | Market Outperform → Market Outperform | |||
11/02/2023 | -41.34% | Morgan Stanley | $22 → $23 | Maintains | Equal-Weight | |||
10/11/2023 | -23.49% | Guggenheim | → $30 | Reiterates | Buy → Buy | |||
09/26/2023 | -28.59% | HC Wainwright & Co. | → $28 | Initiates | → Buy | |||
09/25/2023 | -23.49% | Guggenheim | $27 → $30 | Maintains | Buy | |||
09/13/2023 | -41.34% | Stifel | → $23 | Reiterates | Hold → Hold | |||
09/13/2023 | -18.39% | Truist Securities | → $32 | Reiterates | Buy → Buy | |||
08/22/2023 | -26.04% | Oppenheimer | $25 → $29 | Maintains | Outperform | |||
08/22/2023 | -31.14% | JMP Securities | $24 → $27 | Maintains | Outperform | |||
08/08/2023 | -54.09% | SVB Leerink | → $18 | Initiates | → Market Perform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Exelixis (EXEL)?
El último precio objetivo de Exelixis (NASDAQ:EXEL) fue comunicado por Morgan Stanley el septiembre 17, 2025. La firma de analistas fijó un precio objetivo para $50.00 que espera EXEL a rise dentro de 12 meses (un posible 27.52% upside). 62 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Exelixis (EXEL)?
La última calificación de analistas para Exelixis (NASDAQ:EXEL) fue proporcionada por Morgan Stanley, y Exelixis mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Exelixis (EXEL)?
La última revisión al alza de Exelixis Inc se produjo en junio 24, 2025, cuando Stephens & Co. elevó su precio objetivo a $60. Stephens & Co. anteriormente tenía an equal-weight para Exelixis Inc.
¿Cuándo fue la última revisión a la baja de Exelixis (EXEL)?
La última revisión a la baja de Exelixis Inc se produjo en febrero 24, 2025, cuando Wells Fargo cambió su precio objetivo de $36 a $36 para Exelixis Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Exelixis (EXEL)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Exelixis, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Exelixis se registró el septiembre 17, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 17, 2026.
¿Es correcta la calificación de los analistas sobre Exelixis (EXEL)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Exelixis (EXEL) fue un mantuvo con un precio objetivo de $46.00 a $50.00. El precio actual al que cotiza Exelixis (EXEL) es de $39.21, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.